M&A / Deals Parabilis follows hefty Regeneron deal with IPO push BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritisNext: Beam one-ups Wave as both show promise of genetic editing for AATD Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
